Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
| ▸ | DUT | P33316 | 4/20 | 0.48 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11222933 | 0.86 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL11222942 | 0.86 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL8182745 | 0.86 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL8182746 | 0.86 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL11222936 | 0.86 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL1364671 | 0.85 | DUT (0.61) | DUTP2RY2P2RY4 | |
| SCHEMBL18503452 | 0.85 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL9331385 | 0.84 | DUT (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL9331387 | 0.84 | DUT (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL4366636 | 0.83 | DUT (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | SLC28A1 82/4885SLC28A2 32/4885SLC29A1 165/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | SLC28A1 79/4885SLC28A2 31/4885SLC29A1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.